Law360 has named Sidley’s Global Life Sciences group a 2019 “Practice Group of the Year.” These awards “honor the law firms behind the litigation wins and major deals that resonated throughout the legal industry in the past year.”
In many ways, 2019 was an exceptionally impressive year for Sidley’s Global Life Sciences team. A few notable successes include: the high-stakes jury trial on a Bayer patent asserted against Baxalta, in which the jury returned a damages award that ranks among the 10 largest patent verdicts in Delaware in the past decade and constitutes the largest biotech patent verdict in that court; Fortive Corporation in its acquisition of Johnson & Johnson’s Advanced Sterilization Products division for approximately US$2.7 billion in cash (one of the largest medtech deals in 2019); and the patent win for Amgen’s rheumatoid arthritis drug Enbrel®, the world’s fifth best-selling biologic. The team also represented the most Hong Kong biotech IPOs since the new listing regime went into effect in 2018.
Sidley’s Global Life Sciences practice comprises more than 200 lawyers across numerous disciplines advising clients on three continents. Our base of prominent life sciences clients includes manufacturers, providers, insurers, and private equity and other investors in the sector. Our global group works together as a cohesive unit to provide high-caliber legal advice on the full scope of FDA and healthcare regulatory and compliance, transactional, litigation, and intellectual property and patent litigation matters.